The present study is the first clinical study to show that the oral TPO-RA lusutrombopag could reduce the need for platelet transfusion in CLD patients undergoing invasive procedures while making a proactive assessment of the PVT risk. Here, TPO is linked to congenital secretory chloride diarrhea 1.